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Importance of pre-eclampsia 
Preeclampsia is a hypertensive disorder occurring during pregnancy which complicates 
about 3–5% of all gestations and is estimated to cause at least 42 000 maternal deaths 
every year.1–3 Additionally, for every maternal death related to preeclampsia, at least 50–
100 women have substantial morbidity (figure 1).2,4,5   
	
Figure 1. Posterior risks later in life after development of preeclampsia during pregnancy. 
 
It can present in many ways; the more severe cases are diagnosed after a woman 
presents with seizures, severe epigastric pain, breathlessness, and, often, massive 
placental abruption; however, it can also be diagnosed at a routine antenatal 
appointment in a completely asymptomatic woman who is found to be hypertensive. 
Although a treatment which could modify disease progression has been keenly sought, 
the only current approaches that have demonstrated to improve maternal and fetal 
outcomes in preeclampsia are prevention, early diagnosis and stratification of pregnancy 
care. In cases diagnosed very prematurely when baby’s chance of survival without major 
impairment outside the mother’s uterus is small, the mainstay is expectant management 
and timing birth to optimize perinatal outcome. On the other hand, in cases diagnosed 
later in pregnancy when the fetus is sufficiently mature, the goal is to deliver the baby 
before the onset of complications.  
 
Diagnosis and clinical definitions  
Preeclampsia is a progressive hypertensive disorder of pregnancy that involves multiple 





































and proteinuria with or without skin edema to a much broader classification which 
recognizes the complexity of the multi-organ disfunction caused by the disease. 
Nowadays, international guidelines agree that preeclampsia can be defined as new-
onset hypertension (persistent systolic blood pressure at ≥140 mm Hg or diastolic blood 
pressure at ≥90 mm Hg, or both, more than four hours apart) together with proteinuria, 
or signs or symptoms of organ dysfunction after 20 weeks’ gestation (table 1), or both.6-
10 
 
Table 1. Clinical diagnosis of pre-eclampsia*  
Gestational hypertension (defined as systolic blood pressure ≥140 mm Hg, or diastolic blood pressure 
≥90 mm Hg, or both, persistent more than 4 hours apart) together with one or more of the following new-
onset conditions at or after 20 weeks’ gestation:  
• Proteinuria (e.g., protein to creatinine ratio of ≥30 mg/mmol [0.3 mg/mg])  
• Other maternal organ dysfunction, including:  
• acute kidney injury (creatinine ≥90 μmol/L [1 mg/dL]) and/or 
• liver involvement (elevated alanine aminotransferase or aspartate 
aminotransferase >40 IU/L) with or without right upper quadrant or epigastric abdominal pain  
• Neurological complications (e.g., eclampsia, altered mental state, blindness, stroke, clonus, 
severe headaches, or persistent visual scotomata)  
• Hematological complications (e.g., platelet count <150 000 platelets per μL, disseminated 
intravascular coagulation, or hemolysis)  
• Uteroplacental dysfunction (e.g., fetal growth restriction, abnormal umbilical artery Doppler 
wave form analysis, or stillbirth)  
* According to the International Society for the Study of Hypertension in Pregnancy.10  
 
Signs and symptoms of organ affection by preeclampsia include first, severe 
headache, visual disturbances or eclamptic seizures when the brain is affected; second, 
epigastric pain and/or abnormal liver function tests as a reflection of liver disfunction; 
third, abnormal renal function test and/or proteinuria when the kidneys are impaired; 
fourth, hemolysis, thrombocytopenia and/or coagulopathy which show hematological 
system failure; fifth, pulmonary edema and/or low oxygen saturation; and sixth, fetal 
growth restriction when placental function is insufficient (figure 2).6-11 
However, diagnosis is often challenging specially in those cases where there is 
already an existing hypertension or kidney disease and in the absence of known risk 
factors. Additionally, the management of the disease is more complicated the later in the 




Figure 2. Signs and symptoms of organ affection by preeclampsia. 
 
Risk factors 
Clinical risk factors for preeclampsia are summarized in table 2.12,13 Some risk 
factors for developing preeclampsia during pregnancy may be more amendable than 
others. For example, interventions including weight reduction, avoiding multifetal 
pregnancies from assisted reproduction technologies or optimally treating chronic 
medical conditions (e.g., systemic lupus erythematosus and chronic hypertension) might 
be beneficial in reducing the risk of preeclampsia. 
 
Table 2. Clinical risk factors for developing preeclampsia during pregnancy 
Risk factor 
Pooled unadjusted relative 
risk (95% CI)12 
Unadjusted relative risk 
(95% CI)13 
Prior pre-eclampsia  8·4 (7·1–9·9) 7·19 (5·85–8·83) 
Chronic hypertension  5·1 (4·0–6·5) ·· 
Pregestational diabetes  3·7 (3·1–4·3) 3·56 (2·54–4·99) 
Maternal age <17 years  ·· 2·98 (0·39–22·76) 
Multifetal pregnancy  2·9 (2·6–3·1) 2·93 (2·04–4·21) if twin, 2·83 
(1·25–6·40) if triplet 
Family history of pre-eclampsia  ·· 2·90 (1·70–4·93) 
Antiphospholipid syndrome  2·8 (1·8–4·3) 9·72 (4·34–21·75) 
Pre-pregnancy body-mass 
index >30 kg/m²  
2·8 (2·6–3·1) ·· 
Systemic lupus erythematosus  2·5 (1·0–6·3) ·· 
Previous stillbirth  2·4 (1·7–3·4) ·· 
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Nulliparity  2·1 (11·9–2·4) 2·91 (1·28–6·61) 
Previous placental abruption  2·0 (1·4–2·7) ·· 
Assisted reproductive 
technologies  
1·8 (1·6–2·1) ·· 
Chronic kidney disease  1·8 (1·5–2·1) ·· 
Maternal age >40 years  1·5 (1·2–2·0) 1·68 (1·23–2·29) if 
primiparous, 1·96 (1·34–2·87) 
if multiparous 
Fetal growth restriction  1·4 (0·6–3·0) ·· 
Maternal age >35 years  1·2 (1·1–1·3) ·· 
 
Pathophysiology 
A two-stage approach is currently accepted to describe the pathogenesis of 
preeclampsia. In normal pregnancy, the placenta remodels local uterine vasculature 
during the first weeks of gestation, setting up optimal conditions for maternal-fetal 
nutrient and oxygen exchange all throughout pregnancy. To achieve this, important 
modifications in the uterine blood vessels occur to end up converting the utero-placental 
territory in a high-capacitance, low-resistance system.14 
Impaired vascular remodeling is present in many preeclamptic women and very 
often when the disease results in premature birth with fetal growth restriction.11,15 The 
consequent underperfusion causes placental ischaemia16 and oxidative stress,17,18 which 
damage the placenta, and lead to abnormal angiogenic protein levels in the maternal 
circulation.19  
In addition to this impaired placentation, a potentially major contributor in the 
development of preeclampsia is immunological mismatching between maternal and 
paternal antigens which may occur following the vascular damage.17 From the second 
trimester, a diseased placenta progressively secretes increased amounts of anti-
angiogenic factors together with decreased levels of the pro-angiogenic ones, which 
ultimately cause vascular inflammation, endothelial dysfunction, and maternal vascular 
injury.17 The net result of this altered angiogenic profile is the clinical manifestation of 
hypertension and injury to multiple maternal organs (table 3). 
 
Table 3. Patogenesis of preeclampsia 
Stage 1 Impaired uterine spiral artery transformation Placental oxidative stress and ischaemia . Disrupted 
development of placental villi  
Stage 2 Release of placental factors into maternal circulation Pro-angiogenic and anti-angiogenic 
imbalance systemic maternal endothelial activation. Vascular injury and hypertension  
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Among the many factors secreted in excess by the preeclamptic placenta that 
could contribute to endothelial dysfunction, anti-angiogenic molecules such as soluble 
fms-like tyrosine kinase-1 (sFlt1)20,21 combined with suppression of the release of pro-
angiogenic placental growth factor (PlGF) have been a subject of study in many recent 
trials aiming to improve perinatal outcome. An imbalance between pro- and anti-
angiogenic factors (e.g., increased sFlt-1 / PlGF ratio) results in a net antiangiogenic 
state that favors the development of placental disfunction.22,23 
 
Second- or third-trimester preeclampsia prediction 
Angiogenic factors (e.g., PlGF alone or sFlt-1 / PlGF ratio) with or without information on 
maternal clinical characteristics may facilitate second- or third-trimester prediction of 
early- and late-onset preeclampsia in women who are asymptomatic at the time of the 
analysis.24-29 
The pivotal PRediction of short-term Outcome in preGNant wOmen with 
Suspected preeclampsIa Study (PROGNOSIS) study evaluated the role of the sFlt-1 / 
PlGF ratio for predicting absence or presence of preeclampsia in 1 050 women with 
suspected preeclampsia (24+0 to 36+6 weeks’ gestation), therefore symptomatic. This 
prospective, multicenter study derived and validated an sFlt-1/PlGF ratio of ≤38 for ruling 
out preeclampsia within 1 week.24 The clinical utility of finding a way of accurately 




Many new trials have evaluated the role of angiogenic factors in the prediction of 
preeclampsia in asymptomatic women over the past few years. However, the predictive 
values are varied due to the differences in gestational age at blood sampling, 
characteristics of populations (low- vs. high-risk), predictors (PlGF alone or combined 
models), types of studies (case-control vs. cohort) or pregnancy outcomes (severity of 
preeclampsia or combined preeclampsia with other complications). Therefore, the aim 
of this study was to evaluate the diagnostic accuracy of PlGF from second trimester 
onwards, for the prediction of preeclampsia in asymptomatic women at any time during 
pregnancy. 
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Hypothesis and objectives 
 
Hypothesis  
PlGF is an accurate test to identify asymptomatic women during their second or third 
trimester of pregnancy who will subsequently develop preeclampsia. 
 
Objectives  
- To identify all relevant studies reporting on diagnostic accuracy of maternal 
serum PlGF alone or in combination with sFlt-1 and / or maternal factors 
performed either at the second or at the third trimester to predict subsequent 
development of preeclampsia. 
- To estimate the predictive accuracy of each method; e.g. to estimate an average 
summary value of sensitivity and specificity with their 95% confidence intervals 
(CI) for studies reporting on the same threshold and to estimate a summary 
receiver-operating characteristic (SROC) curve for studies reporting on the same 
test but different thresholds. 
- To select the single best method to screen for preeclampsia in asymptomatic 
women during their second or third trimester of pregnancy by comparing the 




Type of study  
This is a systematic review and meta-analysis including cohort studies reporting on the 
accuracy of PlGF alone and / or PlGF combined with sFlt-1 and / or maternal factors for 
the prediction of preeclampsia in asymptomatic women during their second or third 
trimester of gestation.  
The 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines was followed for reporting this systematic review.30 The study 
protocol was registered in PROSPERO (CRD 42020162460, appendix 1).31  
Search strategy 
Keywords and MeSH terms (preeclampsia, aspirin, angiogenic factors, PlGF) 
related to the role of PlGF for prediction of preeclampsia were searched in MEDLINE via 
PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL), 
ClinicalTrials.GOV and World Health Organization International Clinical Trials Registry 
Platform (WHO-ICTRP) from Jan 1, 1985 to April 15, 2021 (appendix 2). Language 
restrictions were not applied.  
A two-stage process was followed to select studies for inclusion. First, two 
independent reviewers screened the titles and abstracts to identify eligible studies and, 
second, retrieval and assessment of the full text when deemed necessary. Any 
disagreements were resolved after discussion with a third reviewer.  
 
Study selection criteria  
- Inclusion criteria 
1. Original research on pregnant women about PlGF or PlGF combining with 
other biomarkers in blood, serum, or plasma and / or maternal factors for the 
prediction of preeclampsia;  
2. Cohort study;   
3. Gestational age at blood sampling >18 weeks’ gestation; 
4. Singleton pregnancies; 
5. Pregnant women with no signs or symptoms of preeclampsia at the time of 
PlGF testing;  
6. Data available to construct a 2x2 table for calculating the predictive 
performance or diagnostic accuracy of the test;  
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- Exclusion criteria 
1. Case-control, cross-sectional, case-series or case-report studies; 
2. Signs or symptoms of preeclampsia presenting at the time of blood sampling; 
3. Studies reporting the differences in mean values of PlGF between the groups 
or studies which do not allow construction of the 2x2 tables to determine 
predictive performance; 
4. Multiple or non-viable pregnancies included; 
5. Preeclampsia is not an outcome of interest; 
6. PlGF used for the diagnosis rather than prediction of preeclampsia;  
7. Studies where PlGF was used in a contingent or longitudinal model. 
 
Study data extraction 
For each included study, two reviewers independently extracted the following data using 
standardized and previously piloted data extraction forms: first author, publication year, 
country, study design, outcome definition, characteristics of the women, index test 
definition and 2x2 tables according to this, other predictor variables, outcomes and other 
data needed for meta-analysis.  
Authors were contacted directly when further clarification on their data were 
required, such as the diagnostic performance according to singleton and multiple 
pregnancies, missing data, or test performance for preeclampsia as an outcome of 
interest.  
 
Methodological quality assessment of the selected studies 
The methodological quality of the selected studies was assessed by the Quality 
Assessment tool for Diagnostic Accuracy Studies (QUADAS-2).32 This tool comprises 
four domains; each one is assessed in terms of risk of bias and the first three are also 
assessed in terms of concerns regarding applicability. 
Risk of bias 
- The first domain relates to patient selection. A study was considered to be at low 
risk of bias if the index test (PlGF alone or in combination as described above) 
was carried out in a consecutive or random sample of patients. 
- The second domain relates to the index test. A study was considered to be at low 
risk of bias if the index test was carried out and the results given by the laboratory 
were without prior knowledge of the pregnancy outcome (development of 
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subsequent preeclampsia) and the threshold to categorize screened positive 
patients and screened negative patients according to the index test should have 
been prespecified before analysis. This means, the classification between 
screened positive or negative must be blinded to the outcome and the threshold 
clearly stated in advance. 
- The third domain relates to the reference standard. A study was considered to 
be at low risk of bias if the method of diagnosing the disease (preeclampsia) 
under investigation was able to give the correct answer. This means that the 
reference standard used to classify the outcome must be appropriate to diagnose 
the condition without misclassifying cases and this classification must be carried 
out without knowledge of the results from the index test. Therefore, the person 
getting the outcome and deciding if the patient had or didn’t have preeclampsia 
should not know the results from the biomarkers and follow prespecified and clear 
criteria which are likely to detect the disease when present and to exclude it when 
absent. 
- The fourth domain relates to flow the of patients within the study and the timing 
between test and the assessment of the disease status. A study was considered 
to be at low risk of bias if first, in the calculation of performance of screening, all 
patients in the study population had a result from both the PlGF (alone or 
combined) test and pregnancy outcome and, second, if the method of classifying 
the outcome result (preeclampsia diagnostic criteria) was the same in all cases 
in the study population.  
Concerns regarding applicability 
- For the first domain we questioned if the way of selecting the study population 
somehow biasing the results one way or another (e.g. previously screened 
patients). Generally, an unselected population will present a low risk. 
- For the second domain, we evaluated if there were concerns that the PlGF test, 
the way it has been performed or interpreted might be affecting the estimated 
diagnostic accuracy. I.e., studies were the test was interpreted by the same 
clinician assessing the outcome would present concerns regarding applicability 
as well as studies where the technology used for the study was far superior than 
the one routinely used in clinical practice. 
- Last, for the third domain, we judged if there were concerns that the condition 
(preeclampsia) as defined by the reference standard in that particular study might 
not match the research question. I.e., the authors might state that preeclampsia 
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is high-blood pressure and proteinuria, but the thresholds to define any of these 
two criteria might not be appropriate or stated. 
 
Outcome 
The main outcome was preeclampsia occurring at any time during the second or third 
trimester according to the definition used in the primary study. Nonetheless, definition 
was recorded and coded to enable comparisons with other studies. 
 
Data extraction and statistics 
Construction of the 2x2 tables and accuracy estimation of the PlGF test from the primary 
studies  
For each particular threshold reported in each one of the primary studies, classification 
of disease status (development of preeclampsia, yes or no) according to the reference 
standard and to the PlGF test were tabulated into 2x2 tables (Table 4).  
The PlGF test, with or without sFlt-1 or maternal factors, is a continuous variable. 
Therefore, “positivity” or “negativity” from this testing depends on the positivity threshold 
set, in such a way that, results about the selected threshold would test positive and, 
those below, would test negative, converting the results into a dichotomous variable. For 
this reason, both, sensitivity and specificity vary with different thresholds: one increasing 
while the other decreasing when the threshold moves in one direction (i.e. to a higher 
value) and the former increasing and the later decreasing when the threshold moves in 
the opposite direction (i.e. to a lower value). 
 
Table 4. Classification of PlGF test results and preeclampsia status (2x2 table) 
Preeclampsia outcome 
(index test) 
Disease status (truth) 
Total 
Preeclampsia (D+) Non-Preeclampsia (D-) 
PlGF test positive (T+)  True positives (a)  False positives (b)  
PlGF test positives 
(a+b) 
PlGF test negative (T-)  False negatives (c)  True negatives (d)  






cases (b+d)  
N (a+b+c+d) 
 
For estimation of test accuracy, we computed sensitivity, specificity and 
diagnostic test accuracy for each reported threshold in each one of the included studies. 
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Both, sensitivity and specificity are defined conditional on the preeclampsia status and 
therefore they were computed as proportions of the number of preeclamptic and non-
preeclamptic cases, respectively. 
- Sensitivity, expressed as a proportion, was defined as the probability that the 
PlGF test was positive in a case that developed preeclampsia later on in 
pregnancy (formally, sensitivity = P(T+|D+), as a/(a+c) using the numbers from 
table 4. 
- Specificity, also expressed as a proportion, was defined as the probability that 
the PlGF test was negative in a case that did not develop preeclampsia later on 
in pregnancy (formally, specificity = P(T-|D-), as d/(b+d) using the numbers from 
table 4. 
- The diagnostics odds ratio (DOR) was defined as a single number to summarize 
the diagnostic accuracy of the PlGF test representing how many times more likely 
it was to develop preeclampsia among those women with a positive PlGF test 
result compared to those with a negative PlGF test result. Formally, DOR = 
(sensitivity x specificity) / (1 – sensitivity) x (1 – specificity), as (ad) / bc) using the 
numbers from table 4.  
 
Data Synthesis and Analyses 
Although the main objective of this study was to calculate summary statistics for 
sensitivity and specificity, due to the type of data arising from the literature search, we 
had to redefine the strategy for analysis and the research question to focus on 
comparison of accuracy of different methods for PlGF testing. For this purpose, summary 
SROC plots were computed, to represent the results from each individual study in a ROC 
space where each study contributes to, at least, one sensitivity-specificity point. The size 
of the point in this ROC space represents the precision of the estimate (scaled according 
to the inverse of the standard error of the logit(sensitivity) and logit(specificity)) or the 
sample size. This is the preferred approach to analyze studies where there is little 
consistency in the thresholds used among studies. 
 
*The hierarchical SROC model of Rutter and Gatsonis* 
Unlike meta-analysis of intervention studies which estimate one single intervention effect, 
evaluating test accuracy requires knowledge of two parameters, sensitivity and 
specificity, therefore, dealing with two summary statistics simultaneously. Meta-analysis 
of diagnostic test accuracy must account for the trade-off between sensitivity and 
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specificity as the threshold for positivity varies. This trade-off has been widely recognized 
in the evaluation of diagnostic tests and has led to the development of ROC curves.33 It 
has been previously demonstrated that there is substantial variation among the 
estimates of a test’s sensitivity and specificity across published studies.34,35 One 
important source of between-study variations (and even within a given study) is due to 
different positivity thresholds, but also, study characteristic and technical aspects of the 
test, study settings, experience of operators or patients are potential contributors to 
variability across studies when estimating diagnostic test performance. Therefore, 
misleading conclusions may be raised if simple averaging or pooling of the results is 
performed.  
In the hierarchical SROC (HSROC) model of Rutter and Gatsonis,36,37 the 
observed variation is divided into within- and between-studies components, which each 
component consisting of a systematic or fixed part and a random part to account for the 
aforementioned variability.  
- In the first level, accounting for the within-study variation, the number of positive 
tests from the ith study (yi01 and yi11, or a and b using the numbers from table 4), 
are assumed to be independent and follow binomial distributions where the 
probability of a positive result is given by: 
logit(πij) = (θi + αiXij)e−βXij 
 
Xij denotes the true disease status for cases in the ith cell; 
θi denotes the positivity threshold; 
αi represents the accuracy of the test; 
β denotes the shape parameter (if β = 0, then the ROC curve is symmetric). 
Since β requires information from more than one study to be estimated, for the 
construction of the model it will be assumed constant across the studies and both, 
θi and αi will be allowed to vary. Then, within-study parameters would only be 
identifiable through their prior distributions. 
- In the second level, accounting for the between-study variation, study-level 
parameters form the formula above, θi and αi, are assumed to be normally 
distributed. In the context of ROC analysis, positivity threshold and test accuracy 
are independent test characteristics which bring together the correlation between 
the test’s sensitivity and specificity (conditional independence of θi and αi). The 
accuracy parameter has mean Λ and variance σ2α, while the positivity threshold 
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has mean Θ and variance σ2β. When the shape parameter β = 0, test accuracy 
can be summarized by Λ, which represents the expected accuracy (logDOR), 
resulting in a symmetric curve. 
  
It has been shown that the parametrization of the Rutter and Gatsonis model is 
equivalent to the more familiar bivariate multilevel logistic regression model.38 In this way, 
the HSROC model was fit using standard statistical software (STATA version 16.1) via 
a multilevel logistic regression model and later model coefficients were transformed into 




The search identified 2 028 citations from which we selected 463 abstracts for detailed 
assessment of the full text (figure 3). Finally, 100 published studies met the eligibility 
criteria for qualitative and 29 for quantitative syntheses which will represent the only 
“included studies” for this dissertation.39-67  
 The 28 included studies reported a total of 62 549 pregnancies, included 1 484 
developing preeclampsia at any time during their gestation. 10 studies were performed 
in high-risk patients based on maternal characteristics and / or previous obstetric 
history41,42,44,46,48,53,56,61,63,64 and in the other 18, the PlGF test was performed in an 
unselected population.39,40,43,45,47,49-51,54,55,57-60,62,65-67 20 studies reported on performance 
of PlGF testing for prediction of preeclampsia in the second trimester, including 13 which 
reported on PlGF test alone,39-45,50-53,56,59,63 7 which reported on the sFlt-1 / PlGF 
ratio41,42,48,50,55,60,62 and 5 which reported on PlGF models.43,54,55,65,66 13 studies reported 
on performance of PlGF testing for prediction of preeclampsia in the third trimester, 
including 9 which reported on PlGF test alone,43,47,50,57-60,64,67 6 that reported on sFlt-1 / 
PlGF ratio43,50,55,60,64,67 and 8 that reported on PlGF models.43,47,49,52,55,57,62,67   
 Characteristics of the included studies are summarized in table 5.  
There was a wide difference in the type of PlGF assay test used for each study, 
therefore, important technological differences were expected. Additionally, positivity 
thresholds vary enormously, from raw data cutoffs to percentile of the total sample with 
or without adjustment by gestational age or even multiple of the median transformation 
(MoM). With the exception of the sFlt-1 / PlGF ratio, no other combination was constant 
across studies, and models vary from a few maternal factors in combination with any 
type of PlGF test, to very complex combinations of biochemical and biophysical markers 
together with a detail medical and obstetrical maternal history.  
Additionally, definition of preeclampsia widely varied among the 29 studies. In an 
attempt to simplify them, we grouped similar definitions into still 10 different codes as 


























Figure 3. PRISMA flow diagram. 
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Additional records identified 
through other sources 
(n =  11) 
Records after duplicates removed 
(n =   1924) 
Records screened 
(n =   1924) 
Records excluded 
(n =  1461) 
Full-text articles assessed 
for eligibility 
(n =  463) 
Full-text articles excluded  
(n = 363) 
• Not relevant i.e. not cohort 
study, no predictive 
performance, no 
preeclampsia outcome, 
first trimester articles, no 
full-text, multiple 
pregnancies (n=305)  
• Symptomatic articles 
(n=49)  
• Missing information (n=5) 
• Ongoing study (n=4) 
 
Studies included in 
qualitative synthesis 
(n =  100) 
Studies included in 
quantitative synthesis 
(meta-analysis) 
(n = 29) 
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Quality assessment  
Quality assessment by the QUADAS-2 tool showed a high risk of bias for most of the 
domains (figure 4).  
- Patient selection: As expected, in those studies performed in high-risk 
pregnancies, the risk of bias was found to be high because those patients had 
already received previous testing for preeclampsia. However, no concerns 
regarding applicability arose from them because they were all performed within 
the routine clinical practice.  
- Index test: Most of the studies explored test accuracy from different thresholds 
rather than a predetermined one. Additionally, many of them assessed different 
combinations. Concerns regarding applicability were deemed high. 
- Reference standard: Only a few studies, either because they changed the criteria 
for diagnosis of preeclampsia during the study period or because the researchers 
were involved in both, the assessment of the PlGF test and the classification of 
the outcome, were at high risk of bias. Only the later raised concerns regarding 
their applicability. 
- Flow and timing: As expected in a clinical study, most of the studies did not have 
complete follow up and, occasionally, several samples failed to provide a result.  
 
Figure 4. Quality assessment by the QUADAS-2 tool. 
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Time of testing 
(weeks) 
Positivity threshold 
Madazli 2005 1 R&D systems unselected PlGF 21 to 26 90 mg/dl 
Espinoza 2007 2 R&D systems unselected PlGF 22 to 26 PlGF <280 pg/mL 
Stepan 2007 3 R&D systems high-risk PlGF; Sflt/PlGF ratio 19 to 24 118 pg/mL, 3.15 
Diab 2008 4 R&D systems high-risk PlGF; sFlt-1/PlGF ratio 23 <144, 3.92 
Ohkuchi 2011 2 R&D systems unselected 
PlGF; sFlt-1/PlGF ratio; PlGF, Maternal 
factors (history of PE or gestational 
hypertension, maternal age), MAP  
19 to 25 and  
26 to 31 
> onset thresholds, > 
abnormal thresholds 
Shaker 2011 4 R&D systems high-risk PlGF 22 to 26 <=286.32 pg/mL 
Ghosh 2012 5 
DRG Elisa 
immunoassay kit 
unselected PlGF 20 to 22 <188 





Maternal age, parity, UTPI, PlGF, sFlt, 
Leptin 







PlGF; Maternal factors, PlGF, sFlt-1, UTPI, 
MAP 
30-33 Fixed 10%FPR 
Hanita 2014 7 Elecsys, Roche high-risk sFlt-1/PlGF ratio 29 to 36 5,5 
Lai 2014 6 
Cobas e411, 
Roche 
unselected Maternal factor, PlGF, sFLT-1 30 to 33
+6
 Fixed 5% FPR 
Park 2014 7 Elecsys, Roche unselected PlGF,sFlt-1/PlGF ratio 24 to 27 and 34 to 37 5% or 10% FPR 
Andersen 2016 3 
Kryptor, Thermo 
Fisher 
unselected PlGF, sFlt-1/PlGF ratio 20 to 34 <260 pg/ml, >4 
Andrietti 2016 6 
Cobas e411, 
Roche 
unselected Maternal factors, MAP, UTPI, PlGF, sFlt-1 35 to 37
+6
 Fixed 5% FPR 
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Chaiworapongsa 2016 2 R&D systems high-risk PlGF MoM 24 to 33
+6
 Fixed 15% FPR 
Gallo 2016 6 
Cobas e411, 
Roche 
unselected Maternal factors, PlGF, sFlt-1, UTPI, MAP 19 to 24 Fixed 5% FPR 
Kienast 2016 8 Elecsys, Roche unselected 
sFlt-1/PlGF ratio; Multivariate (BMI, 
previous PE, UTPI, sFlt-1/PlGF ratio) 
18 to 25 6.4, 0.11 
Mathur 2016 9 Alere Triage high-risk PlGF 20-34 <5
th
 percentile 
Tsiakkas 2016 6 
Cobas e411, 
Roche 









Valino  2016 6 Not reported unselected PlGF 35 to 37 <5
th
 percentile 
Tan 2017 3 
RayBiotech ELISA 
kit 
unselected PlGF 28 to 32 <1235 pg/mL 
Birdir 2018 6 
Kryptor, Thermo 
Fisher 
unselected PlGF, sFlt-1/PlGF ratio 32 to 37 80.7 pg/ml, 57.3 
Herraiz 2018 3 
Cobas e411, 
Roche 
high-risk sFlt-1/PlGF ratio 24 to 28 >95
th
 percentile 




unselected Maternal factors, UTPI, MAP, PlGF, sFlt-1  35 to 36
+6
 1 in 10 
Tardif 2018 1 
Cobas e411, 
Roche 
high-risk PlGF, sFlt-1/PlGF ratio 20 to 36 <5
th
 percentile 
Navaratnam 2019 10 
Alere Triage PlGF 
test, DELFIA 
Xpress Perkin-
Elmer and Cobas 
e411, Roche 














Maternal factors,PlGF, Peripheral vascular 
resistance 
19 to 23 10% FPR 




Maternal factor, PlGF, MAP, UTPI, sFlt-1, 
ophthalmic PSV ratio 
19 to 23 10% FPR 




Maternal factors, PlGF, sFlt-1, UTPI, 
opthalmic PSV ratio, MAP 
35 to 37 10% FPR 
R&D = research and development tools; PE = preeclampsia; MAP = mean arterial pressure; UTPI = uterine artery pulsatility index; BMI = body 
mass index; FPR = false positive rate. 
 
Table 6. Codification for different definitions of the outcome of interest, preeclampsia 
PE code Definition 
1 BP >= 140/90 mmHg and proteinuria >= 300 mg/24 h 
2 SBP >=140 mmHg and/or DBP >=90 mmHg and proteinuria (>= 300 mg / 24 h, 2x dipstick of 1+ or 1 with >=2+) (ACOG2002, NHBP working group 
2000) 
3 SBP >140 mmHg and/or DBP >90 mmHg after 20 weeks and proteinuria (>=300 mg/24 h or >=1+ reading on dipstick) (NHBP working group 2000) 
4 SBP >=140 mmHg and/or DBP >= 90 mmHg after 20 weeks’ gestation with proteinuria (>=300 mg / 24 h) (ACOG 2002) 
5 DBP >=110 on any one occasion OR DBP >=90 on 2 or more occasions >= 4 h apart AND proteinuria (300 mg/24 h OR 2x MSU >=4 h apart with 1 g 
albumin per liter or 2+ more on reagent strip OR 0.3 g albumin per liter or 1+ on reagent strip if specific gravity >1.030 and PH<8) ISSHP 1988  
6 SBP >=140 mmHg and/or DBP >= 90 mmHg on at least 2 occasions 4 h apart after 20 weeks, proteinuria (>=300 mg in 24 h or 2 dipsticks of >=2+) 
(ISSHP 2001) 
7 SBP >=140 mmHg or DBP >=90 mmHg on two occasions 4 h apart after 20 weeks and at least one of the following proteinuria (>=300 mg/24 h or 
PCR >=30 mg/mmol or >=2+ on dipstick), renal insufficiency (Cr >1.1 g/dL or 2-fold increase in Cr in the absence of underlying renal disease), liver 
involvement (AST twice the normal level), neuro complications (cerebral or visual symptoms), thrombocytopenia (platelet count < 100,000/uL), or 
pulmonary edema (ISSHP 2001 or ACOG 2013 task force) 
7 BP >=140/90 and proteinuria (>= 300 mg/24 h or repeated >=1+ proteinuria) 
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8 SBP >= 140 mmHg and/or DBP >=90 mmHg and proteinuria (>=1+ dipstick) 
9 BP >=140/90 mmHg with proteinuria (>300 mg / 24 h or dipstick >+1) 
10 SBP >=140 mmHg and/or DBP >= 90 mmHg on at least 2 occasions 4 hours apart after 20 weeks, proteinuria (at least 2+ on dipstick analysis or PCR >30 
mg/mmol) (NICE) 
PE = preeclampsia; BP = blood pressure; SBP = systolic blood pressure; DBP = diastolic blood pressure; PCR = protein to creatinine ratio; ACOG 
= American College of Obstetricians and Gynecologists; NHBP = National High Blood Pressure; Cr = creatinine; AST = aspartate amino 






In view of this massive heterogeneity across studies, we decided to abandon our original 
idea of a) estimating an average summary value of sensitivity and specificity (with 95% 
CI) and b) describing how both parameters varied with changing thresholds. Alternatively, 
we opted for comparing accuracy of the different approaches for PlGF testing arising 
from the literature using the HSROC model of Rutter and Gatsonis. If the goal of a meta-
analysis of diagnostic test accuracy is to help to make sense of apparently conflicting 
study results and identify real differences, mixing results from such heterogenous tests 
would provide uninformative and clinically irrelevant conclusions. Therefore, we 
performed multiple analyses to: 
- Compare test accuracy between the different approaches; 
- Compare test accuracy of each approach when performed at the second 
versus the third trimester; 
- Compare test accuracy when applied to high-risk versus unselected 
population. 
Finally, we also performed sensitivity analysis excluding studies which had 
sampling at a different gestational age range to assess the impact of such difference in 
the overall results.  
Although none of the above comparisons were planned in advance, when 
performing systematic reviews and meta-analysis, the type and quantity of data that are 
located through the literature search make often not possible to fully comply with the 
original protocol, as it was published in PROSPERO. Therefore, although the third 
objective was impossible to meet at this stage, alternative analyses were sought, which 
probably, resulted in more interesting conclusions.  
All analyses were conducted separately in unselected and in high-risk populations. 
 
Comparison of the accuracy of the three different approaches used in the second 
trimester  
Unselected population 
A total of 11 studies were included in this analysis. 7 studies were used to construct the 
SROC curve for the approach of testing by PlGF alone, including 2 of them which 
contributed with more than one positivity threshold; 5 studies to construct the SROC 
curve for the approach of testing by the sFlt-1 / PlGF ratio, including 2 that contributed 
with two thresholds; and 8 studies to construct the SROC curve for the approach of 
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testing a model which combines PlGF with maternal factors +/- other biomarkers, 
including 2 that contributed with two thresholds (table 7). Results are displayed in table 
8 and represented graphically in figure 5.  
 
Table 7. Classification of cases according to the method used for PlGF testing and preeclampsia 
status in unselected population in the 2nd trimester 
Author, year Test Time TP TN FP FN 
Madazli, 2005 PlGF alone 21 to 26 13 102 6 1 
Espinoza, 2007 PlGF alone 22 to 26 76 1536 1452 34 
Ohkuchi, 2011 PlGF alone 19 to 25 1 520 3 35 
Ohkuchi, 2011 PlGF alone 19 to 25 5 504 19 31 
Ohkuchi, 2011 PlGF alone 26-31 16 253 149 9 
Ohkuchi, 2011 PlGF alone 26-31 6 376 26 19 
Ghosh, 2012 PlGF alone 20 to 22 43 575 471 15 
Park, 2014 PlGF alone 24 to 27 5 229 25 3 
Park, 2014 PlGF alone 24 to 27 3 241 13 5 
Andersen, 2016 PlGF alone 20 to 34 80 1017 461 37 
Tan, 2017 PlGF alone 28 to 32 19 429 395 0 
Park, 2014 sFlt-1 / PlGF ratio 24 to 27 6 229 25 2 
Park, 2014 sFlt-1 / PlGF ratio 24 to 27 6 241 13 2 
Kienast, 2016 sFlt-1 / PlGF ratio 18 to 25 26 203 95 22 
Kienast, 2016 sFlt-1 / PlGF ratio 28 to 32 41 212 86 7 
Andersen, 2016 sFlt-1 / PlGF ratio 20 to 34 77 941 537 40 
Kienast, 2016 PLGF model 18 to 25 38 232 66 10 
Kienast, 2016 PLGF model 28 to 32 40 241 57 8 
Gallo, 2016 PLGF model 19 to 24 102 7106 374 166 
Gallo, 2016 PLGF model 19 to 24 144 6732 748 124 
Ohkuchi, 2011 PLGF model 19 to 25 23 512 50 13 
Ohkuchi, 2011 PLGF model 26-31 19 375 27 6 
Sapantzoglou, 2021 PLGF model 19 to 23 48 2456 273 28 
Gibbone, 2021 PLGF model 19 to 23 39 2499 278 37 
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Table 8. Estimates from the HSROC random effects model to compare the three PlGF methods when performed in unselected population in the 2nd trimester 
2nd trimester approach 
Estimates 
beta DOR Lambda s2 alpha Theta s2 theta 
PlGF alone -0.05 (-0.54, 0.43) 7.10 (3.56, 14.17) 2.01 (1.19, 2.82) 0.92 (0.24, 3.56) -0.90 (-1,86, 0.05) 2.38 (0.97, 5.87) 
sFlt-1 / PlGF ratio 0.60 ( -0.59, 1.78) 11.30 (3.43, 37.28) 2.39 (1.19, 3.59) 1.32 (0.23, 7.78) 0,11 (-0,59, 0.82) 0.12 (0.01, 1.23) 

































sFlt-1 / PlGF ratio
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These results show that: 
a) the SROC curves are symmetric  as we cannot exclude the beta coefficient 
to be zero, showing that sensitivity and specificity don’t vary differently with 
different positivity thresholds. The higher beta was obtained for sFlt-1 / PlGF 
ratio and likely reflecting that the distribution of this biomarker is not as 
perfectly defined in one of the two groups (probably the cases) as in the other;  
b) similar accuracy for both, the sFlt-1 / PlGF ratio and the PlGF models, which 
a huge overlapping in CI of Lambda accuracy parameter; 
c) lower accuracy for the PlGF alone as compared to the other two approaches 
(however, CI are also overlapping), with a higher variance in thresholds. 
High-risk population 
A total of 12 studies were included in this analysis. 6 studies were used to construct the 
SROC curve for the approach of testing by PlGF alone; 5 studies to construct the SROC 
curve for the approach of testing by the sFlt-1 / PlGF ratio, including 2 that contributed 
with more than one threshold; and 1 only study reporting on PlGF models, which, 
although presenting two available thresholds, made impossible construct the SROC 
curve for this approach (table 9). Results are displayed in table 10 and represented 
graphically in figure 6.  
 
Table 9. Classification of cases according to the method used for PlGF testing and preeclampsia status in 
high-risk population in the 2nd trimester 
Author, year Test Time TP TN FP FN 
Diab, 2008 PlGF alone 23 29 61 14 4 
Stepan, 2007 PlGF alone 19 to 24 9 31 20 3 
Tardif, 2018 PlGF alone 20 to 36 2 56 3 6 
Mathur, 2016 PlGF alone 20-34 20 78 2 0 
Shaker, 2011 PlGF alone 22 to 26 14 77 18 3 
Chaiworapongsa, 2016 PlGF alone 24 to 33+6  20 242 43 9 
Hanita, 2014 sFlt-1 / PlGF ratio 29 to 36 11 49 23 1 
Herraiz, 2018 sFlt-1 / PlGF ratio 24 to 28 25 167 34 15 
Herraiz, 2018 sFlt-1 / PlGF ratio 24 to 28 15 196 5 25 
Herraiz, 2018 sFlt-1 / PlGF ratio 24 to 28 12 198 3 28 
Diab, 2008 sFlt-1 / PlGF ratio 23 33 64 11 0 
Stepan, 2007 sFlt-1 / PlGF ratio 19 to 24 7 26 25 5 
Stepan, 2007 sFlt-1 / PlGF ratio 19 to 24 9 37 14 3 
Tardif, 2018 sFlt-1 / PlGF ratio 20 to 36  2 55 4 6 
Diguisto, 2013 PLGF model 20 to 24 19 161 18 37 
Diguisto, 2013 PLGF model 20 to 24 32 143 36 24 
 27 




beta DOR Lambda s2 alpha Theta s2 theta 
PlGF alone -0.08 (-0.84, 0.68) 14.13 (5.19, 38.48) 2.70 (1.55, 3.86) 1.51 (0.35, 6.48) -0.68 (-1.67, 0.30) 1.51 (0.51, 4.47) 
sFlt-1 to PlGF -0.31 (-1.50, 0.88) 26.49 (5.84, 120.30) 3.39 (1.79, 4.99) 2.75 (0.50, 15.11) -0.49 (-1.58, 0,60) 0.46 (0.10, 2.26) 
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These results show that: 
a) the SROC curves are pretty symmetric showing that sensitivity and specificity 
don’t vary differently with different positivity thresholds and likely reflecting 
that the distribution of biomarkers have similar shape in cases and controls ;  
b) lower accuracy for the PlGF alone as compared to the sFlt-1 / PlGF ratio, 
although overlapping CI of Lambda accuracy parameter. 
 
Sensitivity analysis to exclude studies where sampling was beyond the 2nd trimester 
Since, for some studies, maternal blood sampling for PlGF testing was not only 
conducted during the second trimester but also beyond the 28th week of gestation, we 
constructed a new SROC curve for the three methods to ensure the results remained 
stable whose estimates are shown in table 11.  No significant differences were noted. 
 
Comparison of the accuracy of the three different approaches used in the third trimester  
Unselected population 
A total of 12 studies were included in this analysis. 8 studies were used to construct the 
SROC curve for the approach of testing by PlGF alone, including 4 which contributed 
with more than one positivity threshold; 5 studies to construct the SROC curve for the 
approach of testing by the sFlt-1 / PlGF ratio, including 2 that contributed with two 
thresholds; and 8 studies to construct the SROC curve for the approach of testing a 
model which combines PlGF with maternal factors +/- other biomarkers, including 4 that 
contributed with two thresholds (table 12). Results are displayed in table 13 and 
represented graphically in figure 7.  
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Table 11. Estimations from the new SROC curves after removing studies with maternal sampling beyond 28 weeks of gestation. Sensitivity analysis 
PlGF approach Estimates 
unselected beta DOR Lambda s2 alpha Theta s2 theta 
PlGF alone 0.01 (-0.61, 0.63) 8.27 (3.08, 22.22) 2.10 (0.88, 3.33) 1.30 (0.29, 5.86) -1.30 (-2.53, -0.07) 2.45 (0.8, 7.50) 
PlGF models 0.13 (-0.42, 0.16) 12.36 (10.27, 14.88) 2.63 (2.25, 3.01) 0 -0.90 (-1.35, -0.45) 0.31 (0.13, 0.73) 
high risk beta DOR Lambda s2 alpha Theta s2 theta 
sFlt-1 / PlGF ratio 0.03 (-0.88, 0.93) 15.43 ( 4.45, 53.58) 2.72 (1.29, 4.15) 1.92 (0.38, 9.73) -0.65 (-1.78, 0.49) 1.49 (0.43, 5.19) 
 
 
Table 12. Classification of cases according to the method used for PlGF testing and preeclampsia status in unselected population in the 3rd trimester 
Author, year Test Time  TP TN FP FN 
Ohkuchi, 2011 PlGF alone 26-31 16 253 149 9 
Ohkuchi, 2011 PlGF alone 26-31 6 376 26 19 
Garcia-Tizon Larroca, 2014 PlGF alone 30-33 72 3361 373 46 
Garcia-Tizon Larroca, 2014 PlGF alone 30-33 59 3547 187 59 
Garcia-Tizon Larroca, 2014 PlGF alone 30-33 35 3697 37 83 
Park, 2014 PlGF alone 34 to 37 4 229 25 4 
Park, 2014 PlGF alone 34 to 37 3 241 13 5 
Tsiakkas, 2016 PlGF alone 30 to 34+6  102 7247 384 194 
Tsiakkas, 2016 PlGF alone 30 to 34+6  148 6862 769 148 
Valino 2016 PlGF alone 35 to 37 18 3756 132 47 
Tan, 2017 PlGF alone 28 to 32 19 429 395 0 
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Birdir, 2018 PlGF alone 32 to 37 27 631 67 5 
Sarno, 2021 PlGF alone 35 to 37 32 2004 223 28 
Ohkuchi, 2011 sFlt-1 / PlGF ratio 26 to 31 4 398 4 21 
Ohkuchi, 2011 sFlt-1 / PlGF ratio 26 to 31 15 360 42 10 
Park, 2014 sFlt-1 / PlGF ratio 34 to 37 7 229 25 1 
Park, 2014 sFlt-1 / PlGF ratio 34 to 37 4 241 13 4 
Kienast, 2016 sFlt-1 / PlGF ratio 28 to 32 41 212 86 7 
Birdir, 2018 sFlt-1 / PlGF ratio 32 to 37 27 649 49 5 
Sarno, 2021 sFlt-1 / PlGF ratio 35 to 37 38 2004 223 22 
Ohkuchi, 2011 PLGF model 26-31 19 375 27 6 
Garcia-Tizon Larroca, 2014 PLGF model 30-33 89 3361 373 29 
Garcia-Tizon Larroca, 2014 PLGF model 30-33 78 3547 187 40 
Garcia-Tizon Larroca, 2014 PLGF model 30-33 55 3697 37 63 
Lai, 2014 PLGF model 30 to 33+6  63 3547 187 55 
Lai, 2014 PLGF model 30 to 33+6  75 3361 373 43 
Kienast, 2016 PLGF model 28 to 32 40 241 57 8 
Andrietti, 2016 PLGF model 35-37 6/7 w 50 3473 386 11 
Tsiakkas, 2016 PLGF model 30 to 34+6  147 7129 385 87 
Tsiakkas, 2016 PLGF model 30 to 34+6  167 6744 770 67 
Panaitescu, 2018 PLGF model 35 to 36+6 159 12424 654 113 
Panaitescu, 2018 PLGF model 35 to 36+6 187 11888 1190 85 
Panaitescu, 2018 PLGF model 35 to 36+6 202 11456 1622 70 
Sarno, 2021 PLGF model 35 to 37 43 2004 223 17 
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beta DOR Lambda s2 alpha Theta s2 theta 
PlGF alone 0.20 (-0.26, 0.66) 12.22 (8.35, 17.88) 2.29 (1.63, 2.95) 0.30 (0.08, 1.13) -1.03 (-1.60, -0.45) 0.91 (0.39, 2.11) 
sFlt-1 to PlGF -0.02 (-0.58, 0.54) 21.41 (13.03, 35.18) 3.08 (2.39, 3.78) 0.17 (0.01, 2.01) -0.97 (-1.83, -0.12) 0.97 (0.31, 3.08) 
PlGF models 0.62 (0.33, 0.92) 25.68 (21.16, 31.15) 2.83 (2.64, 3.02) 0  -0.44 (-0.78, -0.11) 0.25 (0.11, 0.56) 
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These results, which are similar to those carried out for 2
nd
 trimester testing, show that: 
a) the SROC curves for PlGF alone and the sFlt-1 / PlGF ratio are symmetric as 
we cannot exclude the beta coefficient to be zero, showing that sensitivity and 
specificity don’t vary differently with different positivity thresholds. However, 
since the 95% CI of β from the PlGF models SROC curve does not include 
zero, significant asymmetry is noted, which likely reflects that distribution of 
this biomarker is not as perfectly defined in one of the two groups (probably 
the cases) as in the other 
b) similar accuracy for both, the sFlt-1 / PlGF ratio and the PlGF models, which 
a huge overlapping in CI; 
c) lower accuracy for the PlGF alone as compared to the other two approaches 
(however, CI are also overlapping). 
High-risk population 
There were not sufficient number of studies to construct the SROC curves for any of the 
three methods (table 9).  
 
Table 12. Classification of cases according to the method used for PlGF testing and 
preeclampsia status in high-risk population in the 3rd trimester 
Author, year Test Time TP TN FP FN 
Navaratnam, 2019 PlGF alone 33 to 35+6 15 84 44 7 
Navaratnam, 2019 PlGF alone 33 to 35+6 15 88 40 7 
Navaratnam, 2019 sFlt-1 / PlGF ratio 33 to 35+6 10 116 12 12 
 
Comparison of the accuracy of the three different approaches for unselected versus 
high-risk populations when used in the second trimester  
The estimates for the SROC curves have been already presented in tables 8 and 13. 




Figure 8. Performance of PlGF alone for prediction of total preeclampsia in unselected 
population at the second compared to third trimester.   
 
 
Figure 9. Performance of sFlt-1 / PlGF ratio for prediction of total preeclampsia in 
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Figure 10. Performance of prediction models for prediction of total preeclampsia at the 
second compared to third trimester.   
 
Although not significantly different, the test accuracy in the third trimester seems to be 
higher, which makes perfect sense from the clinical point of view. The type of 
preeclampsia which is known to alter biomarkers the most is the one with an early onset 
(the earlier the onset of the disease the more altered the biomarkers are expected to be) 
as compared to that preeclampsia which happens at term. However, our analysis was 
focused on total preeclampsia and, whilst preeclampsia overall complicates 3-5% of all 
pregnancies, less than 1% will actually require a preterm delivery and, therefore, the vast 
majority of affected cases in this study correspond to term preeclampsia, where 
biomarkers alter less and later. It is likely that, if we had targeted early preeclampsia 
when assessing 2
nd
 trimester approaches, results would improve for the second trimester 
tests but, testing mostly late cases, the event is too far from sampling for the test to be 
able to detect it correctly. 
 
Comparison of the accuracy of the different approaches for unselected versus high-risk 
populations when used in the third trimester 
Due to the limited number of studies performed in high-risk cases during the third 
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testing alone and sFlt-1 / PlGF ratio. Estimates have been already presented in tables 8 
and 10. Graphical representation is shown in figures 11 and 12 
. 
Figure 11. Prediction of total preeclampsia by PlGF alone in unselected population 
compared to high risk population in the second trimester. 
 
 
Figure 12. Prediction of total preeclampsia by sFLT-1/PlGF ratio in unselected 









































Although not significantly different, the test accuracy of both tests, PlGF alone or sFlt-1 
/ PlGF ratio seems higher in higher risk populations. While this is something to expect 
when assessing predictive values which are highly influenced by the prevalence of the 
disease, sensitivity and specificity are intrinsic characteristics of the tests and should not 




- There is a large number of publications evaluating the accuracy of the PlGF 
and its multiple combinations for the prediction of preeclampsia but first, many 
of them are performed under low quality standards, therefore preventing them 
to even been considered for inclusion in a meta-analysis; second, the 
technology, methodology and positivity thresholds used are so 
heterogeneous across studies that trying to summarize test accuracy with an 
overall sensitivity and an overall specificity is not possible; third, the risk of 
bias found in the included articles is high, mostly due to the exploratory nature 
of the vast majority of the studies; and fourth, the number of cases reported 
in the studies is very small, therefore deriving in wide CI. 
- Despite the lack of significant differences among methods, type of population 
or gestational age at sampling, it seems consistent across studies that first, 
those methods which add additional biomarkers or maternal factors to the 
PlGF testing along present a constantly higher accuracy; second, when 
predicting total preeclampsia, PlGF testing in the third trimester, when the 
event is closer in time, appears to present a better performance as compared 
to second trimester testing; and third, for a reason still to be studied, PlGF 
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Review question
This is a two step review trying to solve two different research questions
1- What is the accuracy of PlGF alone or in combination with sFlt-1 or maternal factors to detect
preeclampsia in asymptomatic women?
2- What is the accuracy of PlGF alone or in combination with sFlt-1 or maternal factors to detect adverse
outcome in women with suspected preeclampsia (symptomatic)? 
Population: Pregnant women at risk of developing PE either asymptomatic (to answer research question
one) or presenting with signs or symptoms of PE (to answer research question two)
Index tests: PlGF determination alone, PlGF in combination with sFlt-1 and PlGF in combination with other
maternal factors
Reference standard: high blood pressure and proteinuria or analytical deviations due to multiorgan failure in
pregnancies of more than 20 weeks
Design: cohort or cross-sectional test accuracy studies
Outcome: 1- Detection of preeclampsia as per the definition used in the study for asymptomatic patients / 2-
Detection of adverse outcome in symptomatic patients.
Searches
Keywords and MeSH terms related to the role of PlGF for prediction of preeclampsia were searched in
MEDLINE via PubMed, EMBASE, Cochrane Central Register of Controlled Trials (CENTRAL),
ClinicalTrials.gov and World Health Organization International Clinical Trials Registry Platform (WHO-
ICTRP). Language or time restrictions will not be applied.
Types of study to be included
Inclusion criteria:
1. Cohort or cross-sectional test accuracy studies.
2. Follow up > 85%
3. Serum PlGF alone or combined with sFlt or maternal factors to elaborate the prediction model
4. Have PE outcome and/or perinatal outcome
5. Study that allows to tabulate 2x2 table.
6. Including asymptomatic or suspected PE
7. Singleton pregnancies only
Exclusion
1. Articles reporting only the difference of biomarkers such as median differences (i.e. without predictive
performance) as we cannot use the data to tabulate 2x2 table
2. Missing or loss to FU >15%
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3. Diagnosis of PE at the time of blood sample collection
4. No PE outcome
5. Multiple pregnancies
6. Retrospective study or case series
7. PlGF used to diagnose rather than predict PE (only applicable for research question 1)
Condition or domain being studied
Pre-eclampsia (PE) affects 2-5% of pregnant women and is a leading cause of maternal and perinatal
morbidity/mortality. It is important to early diagnose PE because this condition leads to multiorgan-failure
that if left unmanaged that can lead to seizures, coma and death of both mother and fetus. The cause of PE
remains unclear. Recent evidence suggests that imbalance of placentally derived angiogenic factors may
play an important role. PlGF has been the most studied to diagnose or early detect PE, either alone or in
combination with other biomarkers, mostly sFLt-1, or maternal characteristics. In healthy pregnancies, PlGF
increases with gestation up to the 28th-30th week and start to decline afterwards and it is thought to reduce
vascular resistance in the placenta . In pregnancies complicated by PE, lower concentrations of PlGF have
been demonstrated. This decrease is already evident from the second trimester, before the development of
any clinical signs or symptoms of the disease. There is a wide variation on the predictive performance of
PlGF for PE (detection rates ranging from 40-95%). This lack of homogeneity is currently restricting clinical
implementation of such biomarker in daily practice, reason why we were prompt to conduct this
investigation.
Participants/population
Pregnant women at more than 18 weeks of gestation at risk of preeclampsia either a) asymptomatic or b)
presenting with signs or symptoms of PE before any diagnosis is made.
Intervention(s), exposure(s)
PlGF blood levels analysed to predict pre-eclampsia in patients a) with no signs or symptoms of pre-
eclampsia or b) presenting with signs or symptoms of pre-eclampsia.
Comparator(s)/control
1- Patients without PE in pregnancy for the asymptomatic cases.
2- Patients with PE who do not develop adverse maternal or fetal complications as a consequence of the
disease.
Main outcome(s)
1- Delivery with preeclampsia at any gestational age (research question 1).
2- Development of adverse maternal or fetal complications as a consequence of maternal PE (research
question 2).
Measures of effect
We will use odds ratios and/or relative risks when appropriate
Additional outcome(s)
To answer research question 2, we will include development of any associated or secondary adverse
outcomes:
- Neonatal: growth restriction, preterm birth (spontaneous or iatrogenic due to PE), stillbirth or neonatal
death, grade II (or higher) ventricular hemorrhage, sepsis, severe anemia (requiring transfusion), severe
respiratory distress syndrome (requiring surfactant and ventilation), necrotising enterocolitis requiring
surgical intervention, intensive care unit admission.
- Maternal: maternal death, development of eclampsia, stroke, hepatic rupture, cortical blindness, Glasgow
coma score, blood transfusion, renal dysfunction, placental abruption.
Measures of effect
We will use odds ratios and/or relative risks when appropriate
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Data extraction (selection and coding)
The abstracts of citations will be examined by two reviewers independently (D.C, W.P and P.C, N.C) to
identify all potentially relevant articles, which will then be examined in full-text form. Reference lists of
relevant original and review articles will also be hand-searched for additional reports. Agreement about
potential relevance will be reached by consensus and discrepancies will be solved by discussion with a third
reviewer (M.G or L.P indistinctly). Translation of papers published in other languages than English, Spanish,
Malaysian or Cantonese will be undertaken prior to reviewing. Authors will be contacted when clarifications
are required in the interpretation of their data.
Data will be extracted onto a previously designed form independently and in duplicate by two reviewers.
Data regarding population characteristics will also be collected (age, ethnicity, gestational age, risk factors
for PE) as well as description of the index test (including cut-off used for considering the test positive), the
reference standard (criteria and threshold used to diagnosed PE) and the results from the index test (true
positive, true negatives, false positives and false negatives) to allow creation of 2 x 2 table. All 2 x 2 table
will be reviewed before analysis by M.G to check for consistency and mistakes.
Risk of bias (quality) assessment
Methodological quality of the selected studies will be assessed by the Quality Assessment tool for
Diagnostic Accuracy Studies (QUADAS-2) by two reviewers (D.C, W.P and P.C, N.C) to identify potential
sources of bias. Disagreements between reviewers will be solved by consultation with a third one (M.M.G or
L.P. indistinctly).
Strategy for data synthesis
We will first provide a narrative synthesis of the findings from the included studies to described test accuracy
of identified tests (sensitivity and specificity). Whenever possible, data for each test (PlGF alone and
combined with sFlt-1) will be plotted in the receiving operating space and where possible, we will summarize
estimates of the diagnostic accuracy using hierarchical models to generate a summary operating point
(summary sensitivity and summary specificity) with 95% confidence intervals. We will estimate the 95%
confidence contour and the 95% prediction region. If possible, we will conduct sensitivity analyses based on
type of population (low- and high-risk for PE) study quality (low- and high-risk of bias), test timing and
variation in diagnostic criteria of PE. All analysis will be carried out for both type of populations, symptomatic
and asymptomatic women and differences in accuracy will be studied.
Analysis of subgroups or subsets
If the numbers allow us to do so, we will perform a subgroup analysis according to the timing (at one, two,
three or four weeks before the diagnosis) when the test was performed, type of population examined (high-
risk vs. low-risk for developing PE) and analysis platform used.
Contact details for further information
Liona Poon
chiu_yee_liona.poon@kcl.ac.uk
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Appendix 2. Search strategy 
PICO 
¿Son eficaces los biomarcadores sFlt-1 y PlGF para predecir la preeclampsia a 
partir del segundo trimestre de embarazo en mujeres asintomáticas y 
sintomáticas? 
 (((("Pre-Eclampsia"[Mesh] OR pre-eclampsia[tw] OR preeclampsia[tw]) AND (soluble 
fms-like tyrosine kinase 1[tw] OR sFlt-1[tw] OR placental growth factor[tw] OR PIGF[tw] 
OR PLGF[tw] OR sFlt-1/PlGF [tw] OR soluble fms-like tyrosine kinase 1/placental growth 
factor[tw] OR angiogenic factor[tw] OR "Angiogenesis Inducing Agents"[Mesh] OR 
angiogenic factor*[tw] OR angiogenesis factor*[tw] OR angiogenic biomarkers[tw] OR 
serum markers[tw])))) NOT (("Comment"[Publication Type] OR "Editorial"[Publication 
Type] OR "Letter"[Publication Type] OR "Case Reports"[Publication Type])) 
Ítems = 1716  
((((((("Pre-Eclampsia"[Mesh] OR pre-eclampsia[tw] OR preeclampsia[tw]) AND (soluble 
fms-like tyrosine kinase 1[tw] OR sFlt-1[tw] OR placental growth factor[tw] OR PIGF[tw] 
OR PLGF[tw] OR sFlt-1/PlGF [tw] OR soluble fms-like tyrosine kinase 1/placental growth 
factor[tw] OR angiogenic factor[tw] OR "Angiogenesis Inducing Agents"[Mesh] OR 
angiogenic factor*[tw] OR angiogenesis factor*[tw] OR angiogenic biomarkers[tw] OR 
serum markers[tw])))) NOT (("Comment"[Publication Type] OR "Editorial"[Publication 
Type] OR "Letter"[Publication Type] OR "Case Reports"[Publication Type]))))) NOT 
(("animal experimentation"[MeSH Terms] OR "models, animal"[MeSH Terms] OR 
"invertebrates"[MeSH Terms] OR "Animals"[Mesh:noexp] OR "animal population 
groups"[MeSH Terms] OR "chordata"[MeSH Terms:noexp] OR "chordata, 
nonvertebrate"[MeSH Terms] OR "vertebrates"[MeSH Terms:noexp] OR 
"amphibians"[MeSH Terms] OR "birds"[MeSH Terms] OR "fishes"[MeSH Terms] OR 
"reptiles"[MeSH Terms] OR "mammals"[MeSH Terms:noexp] OR "primates"[MeSH 
Terms:noexp] OR "artiodactyla"[MeSH Terms] OR "carnivora"[MeSH Terms] OR 
"cetacea"[MeSH Terms] OR "chiroptera"[MeSH Terms] OR "elephants"[MeSH Terms] 
OR "hyraxes"[MeSH Terms] OR "insectivora"[MeSH Terms] OR "lagomorpha"[MeSH 
Terms] OR "marsupialia"[MeSH Terms] OR "monotremata"[MeSH Terms] OR 
"perissodactyla"[MeSH Terms] OR "rodentia"[MeSH Terms] OR "scandentia"[MeSH 
Terms] OR "sirenia"[MeSH Terms] OR "xenarthra"[MeSH Terms] OR "haplorhini"[MeSH 
Terms:noexp] OR "strepsirhini"[MeSH Terms] OR "platyrrhini"[MeSH Terms] OR 
"tarsii"[MeSH Terms] OR "catarrhini"[MeSH Terms:noexp] OR "cercopithecidae"[MeSH 
Terms] OR "hylobatidae"[MeSH Terms] OR "hominidae"[MeSH Terms:noexp] OR 
"gorilla gorilla"[MeSH Terms] OR "pan paniscus"[MeSH Terms] OR "pan 
troglodytes"[MeSH Terms] OR "pongo pygmaeus"[MeSH Terms]) OR ((animals[tiab] OR 
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animal[tiab] OR mice[Tiab] OR mus[Tiab] OR mouse[Tiab] OR murine[Tiab] OR 
woodmouse[tiab] OR rats[Tiab] OR rat[Tiab] OR murinae[Tiab] OR muridae[Tiab] OR 
cottonrat[tiab] OR cottonrats[tiab] OR hamster[tiab] OR hamsters[tiab] OR cricetinae[tiab] 
OR rodentia[Tiab] OR rodent[Tiab] OR rodents[Tiab] OR pigs[Tiab] OR pig[Tiab] OR 
swine[tiab] OR swines[tiab] OR piglets[tiab] OR piglet[tiab] OR boar[tiab] OR boars[tiab] 
OR "sus scrofa"[tiab] OR ferrets[tiab] OR ferret[tiab] OR polecat[tiab] OR polecats[tiab] 
OR "mustela putorius"[tiab] OR "guinea pigs"[Tiab] OR "guinea pig"[Tiab] OR cavia[Tiab] 
OR callithrix[Tiab] OR marmoset[Tiab] OR marmosets[Tiab] OR cebuella[Tiab] OR 
hapale[Tiab] OR octodon[Tiab] OR chinchilla[Tiab] OR chinchillas[Tiab] OR 
gerbillinae[Tiab] OR gerbil[Tiab] OR gerbils[Tiab] OR jird[Tiab] OR jirds[Tiab] OR 
merione[Tiab] OR meriones[Tiab] OR rabbits[Tiab] OR rabbit[Tiab] OR hares[Tiab] OR 
hare[Tiab] OR diptera[Tiab] OR flies[Tiab] OR fly[Tiab] OR dipteral[Tiab] OR 
drosphila[Tiab] OR drosophilidae[Tiab] OR cats[Tiab] OR cat[Tiab] OR carus[Tiab] OR 
felis[Tiab] OR nematoda[Tiab] OR nematode[Tiab] OR nematoda[Tiab] OR 
nematode[Tiab] OR nematodes[Tiab] OR sipunculida[Tiab] OR dogs[Tiab] OR dog[Tiab] 
OR canine[Tiab] OR canines[Tiab] OR canis[Tiab] OR sheep[Tiab] OR sheeps[Tiab] OR 
mouflon[Tiab] OR mouflons[Tiab] OR ovis[Tiab] OR goats[Tiab] OR goat[Tiab] OR 
capra[Tiab] OR capras[Tiab] OR rupicapra[Tiab] OR chamois[Tiab] OR haplorhini[Tiab] 
OR monkey[Tiab] OR monkeys[Tiab] OR anthropoidea[Tiab] OR anthropoids[Tiab] OR 
saguinus[Tiab] OR tamarin[Tiab] OR tamarins[Tiab] OR leontopithecus[Tiab] OR 
hominidae[Tiab] OR ape[Tiab] OR apes[Tiab] OR pan[Tiab] OR paniscus[Tiab] OR "pan 
paniscus"[Tiab] OR bonobo[Tiab] OR bonobos[Tiab] OR troglodytes[Tiab] OR "pan 
troglodytes"[Tiab] OR gibbon[Tiab] OR gibbons[Tiab] OR siamang[Tiab] OR 
siamangs[Tiab] OR nomascus[Tiab] OR symphalangus[Tiab] OR chimpanzee[Tiab] OR 
chimpanzees[Tiab] OR prosimians[Tiab] OR "bush baby"[Tiab] OR prosimian[Tiab] OR 
bush babies[Tiab] OR galagos[Tiab] OR galago[Tiab] OR pongidae[Tiab] OR gorilla[Tiab] 
OR gorillas[Tiab] OR pongo[Tiab] OR pygmaeus[Tiab] OR "pongo pygmaeus"[Tiab] OR 
orangutans[Tiab] OR pygmaeus[Tiab] OR lemur[Tiab] OR lemurs[Tiab] OR 
lemuridae[Tiab] OR horse[Tiab] OR horses[Tiab] OR pongo[Tiab] OR equus[Tiab] OR 
cow[Tiab] OR calf[Tiab] OR bull[Tiab] OR chicken[Tiab] OR chickens[Tiab] OR 
gallus[Tiab] OR quail[Tiab] OR bird[Tiab] OR birds[Tiab] OR quails[Tiab] OR poultry[Tiab] 
OR poultries[Tiab] OR fowl[Tiab] OR fowls[Tiab] OR reptile[Tiab] OR reptilia[Tiab] OR 
reptiles[Tiab] OR snakes[Tiab] OR snake[Tiab] OR lizard[Tiab] OR lizards[Tiab] OR 
alligator[Tiab] OR alligators[Tiab] OR crocodile[Tiab] OR crocodiles[Tiab] OR turtle[Tiab] 
OR turtles[Tiab] OR amphibian[Tiab] OR amphibians[Tiab] OR amphibia[Tiab] OR 
frog[Tiab] OR frogs[Tiab] OR bombina[Tiab] OR salientia[Tiab] OR toad[Tiab] OR 
toads[Tiab] OR "epidalea calamita"[Tiab] OR salamander[Tiab] OR salamanders[Tiab] 
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OR eel[Tiab] OR eels[Tiab] OR fish[Tiab] OR fishes[Tiab] OR pisces[Tiab] OR 
catfish[Tiab] OR catfishes[Tiab] OR siluriformes[Tiab] OR arius[Tiab] OR 
heteropneustes[Tiab] OR sheatfish[Tiab] OR perch[Tiab] OR perches[Tiab] OR 
percidae[Tiab] OR perca[Tiab] OR trout[Tiab] OR trouts[Tiab] OR char[Tiab] OR 
chars[Tiab] OR salvelinus[Tiab] OR "fathead minnow"[Tiab] OR minnow[Tiab] OR 
cyprinidae[Tiab] OR carps[Tiab] OR carp[Tiab] OR zebrafish[Tiab] OR zebrafishes[Tiab] 
OR goldfish[Tiab] OR goldfishes[Tiab] OR guppy[Tiab] OR guppies[Tiab] OR chub[Tiab] 
OR chubs[Tiab] OR tinca[Tiab] OR barbels[Tiab] OR barbus[Tiab] OR pimephales[Tiab] 
OR promelas[Tiab] OR "poecilia reticulata"[Tiab] OR mullet[Tiab] OR mullets[Tiab] OR 
seahorse[Tiab] OR seahorses[Tiab] OR mugil curema[Tiab] OR atlantic cod[Tiab] OR 
shark[Tiab] OR sharks[Tiab] OR catshark[Tiab] OR anguilla[Tiab] OR salmonid[Tiab] OR 
salmonids[Tiab] OR whitefish[Tiab] OR whitefishes[Tiab] OR salmon[Tiab] OR 
salmons[Tiab] OR sole[Tiab] OR solea[Tiab] OR "sea lamprey"[Tiab] OR lamprey[Tiab] 
OR lampreys[Tiab] OR pumpkinseed[Tiab] OR sunfish[Tiab] OR sunfishes[Tiab] OR 
tilapia[Tiab] OR tilapias[Tiab] OR turbot[Tiab] OR turbots[Tiab] OR flatfish[Tiab] OR 
flatfishes[Tiab] OR sciuridae[Tiab] OR squirrel[Tiab] OR squirrels[Tiab] OR 
chipmunk[Tiab] OR chipmunks[Tiab] OR suslik[Tiab] OR susliks[Tiab] OR vole[Tiab] OR 
voles[Tiab] OR lemming[Tiab] OR lemmings[Tiab] OR muskrat[Tiab] OR muskrats[Tiab] 
OR lemmus[Tiab] OR otter[Tiab] OR otters[Tiab] OR marten[Tiab] OR martens[Tiab] OR 
martes[Tiab] OR weasel[Tiab] OR badger[Tiab] OR badgers[Tiab] OR ermine[Tiab] OR 
mink[Tiab] OR minks[Tiab] OR sable[Tiab] OR sables[Tiab] OR gulo[Tiab] OR gulos[Tiab] 
OR wolverine[Tiab] OR wolverines[Tiab] OR minks[Tiab] OR mustela[Tiab] OR 
llama[Tiab] OR llamas[Tiab] OR alpaca[Tiab] OR alpacas[Tiab] OR camelid[Tiab] OR 
camelids[Tiab] OR guanaco[Tiab] OR guanacos[Tiab] OR chiroptera[Tiab] OR 
chiropteras[Tiab] OR bat[Tiab] OR bats[Tiab] OR fox[Tiab] OR foxes[Tiab] OR 
iguana[Tiab] OR iguanas[Tiab] OR xenopus laevis[Tiab] OR parakeet[Tiab] OR 
parakeets[Tiab] OR parrot[Tiab] OR parrots[Tiab] OR donkey[Tiab] OR donkeys[Tiab] 
OR mule[Tiab] OR mules[Tiab] OR zebra[Tiab] OR zebras[Tiab] OR shrew[Tiab] OR 
shrews[Tiab] OR bison[Tiab] OR bisons[Tiab] OR buffalo[Tiab] OR buffaloes[Tiab] OR 
deer[Tiab] OR deers[Tiab] OR bear[Tiab] OR bears[Tiab] OR panda[Tiab] OR 
pandas[Tiab] OR "wild hog"[Tiab] OR "wild boar"[Tiab] OR fitchew[Tiab] OR fitch[Tiab] 
OR beaver[Tiab] OR beavers[Tiab] OR jerboa[Tiab] OR jerboas[Tiab] OR capybara[Tiab] 
OR capybaras[Tiab]) NOT medline[subset])) 
Ítems = 1391 
ISSG Search Filters Resource  
Enhancing search efficiency by means of a search filter for finding all studies on animal 
experimentation in PubMed 
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Systematic Reviews/Metaanalysis (animal experimentation filter not applied) 
systematic[sb] AND (((((("Pre-Eclampsia"[Mesh] OR pre-eclampsia[tw] OR 
preeclampsia[tw]) AND (soluble fms-like tyrosine kinase 1[tw] OR sFlt-1[tw] OR placental 
growth factor[tw] OR PIGF[tw] OR PLGF[tw] OR sFlt-1/PlGF [tw] OR soluble fms-like 
tyrosine kinase 1/placental growth factor[tw] OR angiogenic factor[tw] OR "Angiogenesis 
Inducing Agents"[Mesh] OR angiogenic factor*[tw] OR angiogenesis factor*[tw] OR 
angiogenic biomarkers[tw] OR serum markers[tw])))) NOT (("Comment"[Publication 
Type] OR "Editorial"[Publication Type] OR "Letter"[Publication Type] OR "Case 
Reports"[Publication Type])))) Sort by: PublicationDate 
Ítems = 25 
Therapy Filter (animal experimentation filter applied) 
(Therapy/Broad[filter]) AND (((((("Pre-Eclampsia"[Mesh] OR pre-eclampsia[tw] OR 
preeclampsia[tw]) AND (soluble fms-like tyrosine kinase 1[tw] OR sFlt-1[tw] OR placental 
growth factor[tw] OR PIGF[tw] OR PLGF[tw] OR sFlt-1/PlGF [tw] OR soluble fms-like 
tyrosine kinase 1/placental growth factor[tw] OR angiogenic factor[tw] OR "Angiogenesis 
Inducing Agents"[Mesh] OR angiogenic factor*[tw] OR angiogenesis factor*[tw] OR 
angiogenic biomarkers[tw] OR serum markers[tw])))) NOT (("Comment"[Publication 
Type] OR "Editorial"[Publication Type] OR "Letter"[Publication Type] OR "Case 
Reports"[Publication Type])))) Sort by: PublicationDate 
Ítems = 169 
Diagnosis Filter (animal experimentation filter applied) 
(Diagnosis/Broad[filter]) AND (((((("Pre-Eclampsia"[Mesh] OR pre-eclampsia[tw] OR 
preeclampsia[tw]) AND (soluble fms-like tyrosine kinase 1[tw] OR sFlt-1[tw] OR placental 
growth factor[tw] OR PIGF[tw] OR PLGF[tw] OR sFlt-1/PlGF [tw] OR soluble fms-like 
tyrosine kinase 1/placental growth factor[tw] OR angiogenic factor[tw] OR "Angiogenesis 
Inducing Agents"[Mesh] OR angiogenic factor*[tw] OR angiogenesis factor*[tw] OR 
angiogenic biomarkers[tw] OR serum markers[tw])))) NOT (("Comment"[Publication 
Type] OR "Editorial"[Publication Type] OR "Letter"[Publication Type] OR "Case 
Reports"[Publication Type])))) Sort by: PublicationDate 
Ítems = 685 
Prognosis Filter (animal experimentation filter applied) 
(Prognosis/Broad[filter]) AND (((((("Pre-Eclampsia"[Mesh] OR pre-eclampsia[tw] OR 
preeclampsia[tw]) AND (soluble fms-like tyrosine kinase 1[tw] OR sFlt-1[tw] OR placental 
growth factor[tw] OR PIGF[tw] OR PLGF[tw] OR sFlt-1/PlGF [tw] OR soluble fms-like 
tyrosine kinase 1/placental growth factor[tw] OR angiogenic factor[tw] OR "Angiogenesis 
Inducing Agents"[Mesh] OR angiogenic factor*[tw] OR angiogenesis factor*[tw] OR 
angiogenic biomarkers[tw] OR serum markers[tw])))) NOT (("Comment"[Publication 
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Type] OR "Editorial"[Publication Type] OR "Letter"[Publication Type] OR "Case 
Reports"[Publication Type])))) Sort by: PublicationDate 
Ítems = 590 
Clinical Prediction Rules (animal experimentation filter applied) 
(Clinical Prediction Guides/Broad[filter]) AND (((((("Pre-Eclampsia"[Mesh] OR pre-
eclampsia[tw] OR preeclampsia[tw]) AND (soluble fms-like tyrosine kinase 1[tw] OR sFlt-
1[tw] OR placental growth factor[tw] OR PIGF[tw] OR PLGF[tw] OR sFlt-1/PlGF [tw] OR 
soluble fms-like tyrosine kinase 1/placental growth factor[tw] OR angiogenic factor[tw] 
OR "Angiogenesis Inducing Agents"[Mesh] OR angiogenic factor*[tw] OR angiogenesis 
factor*[tw] OR angiogenic biomarkers[tw] OR serum markers[tw])))) NOT 
(("Comment"[Publication Type] OR "Editorial"[Publication Type] OR "Letter"[Publication 
Type] OR "Case Reports"[Publication Type])))) Sort by: PublicationDate 
Ítems = 728 
Observational Studies (animal experimentation filter not applied) 
((((((("Pre-Eclampsia"[Mesh] OR pre-eclampsia[tw] OR preeclampsia[tw]) AND (soluble 
fms-like tyrosine kinase 1[tw] OR sFlt-1[tw] OR placental growth factor[tw] OR PIGF[tw] 
OR PLGF[tw] OR sFlt-1/PlGF [tw] OR soluble fms-like tyrosine kinase 1/placental growth 
factor[tw] OR angiogenic factor[tw] OR "Angiogenesis Inducing Agents"[Mesh] OR 
angiogenic factor*[tw] OR angiogenesis factor*[tw] OR angiogenic biomarkers[tw] OR 
serum markers[tw])))) NOT (("Comment"[Publication Type] OR "Editorial"[Publication 
Type] OR "Letter"[Publication Type] OR "Case Reports"[Publication Type]))))) AND 
(((Cohort Studies[tw] OR cohort study[tw] OR Follow-Up Studies[tw] OR follow-up 
study[tw] OR Prospective Studies[tw] OR prospective study[tw] OR Longitudinal 
Studies[tw] OR longitudinal study[tw] OR longitudinal survey[tw] OR longitudinal 
surveys[tw] OR Retrospective Studies[tw] OR retrospective studies[tw] OR retrospective 
study[tw] OR Case-Control Studies[tw] OR case-control[tw] OR case-controls[tw] OR 
cases-controls[tw] OR case-controlled[tw] OR "cases and controls"[tw]))) Sort by: 
PublicationDate 
Ítems = 663 
Cost Analysis Studies 
((((((("Pre-Eclampsia"[Mesh] OR pre-eclampsia[tw] OR preeclampsia[tw]) AND (soluble 
fms-like tyrosine kinase 1[tw] OR sFlt-1[tw] OR placental growth factor[tw] OR PIGF[tw] 
OR PLGF[tw] OR sFlt-1/PlGF [tw] OR soluble fms-like tyrosine kinase 1/placental growth 
factor[tw] OR angiogenic factor[tw] OR "Angiogenesis Inducing Agents"[Mesh] OR 
angiogenic factor*[tw] OR angiogenesis factor*[tw] OR angiogenic biomarkers[tw] OR 
serum markers[tw])))) NOT (("Comment"[Publication Type] OR "Editorial"[Publication 
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Type] OR "Letter"[Publication Type] OR "Case Reports"[Publication Type]))))) AND 
("Costs and Cost Analysis"[Mesh] OR cost[tw] OR costs[tw]) Sort by: PublicationDate 
Ítems = 32 
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